{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:06:03Z","timestamp":1787166363978,"version":"build-2736575974"},"reference-count":52,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci Atheroscler Dis"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is known to have high prevalence in obese patients, and has been found to be associated with the metabolic syndrome (MetS). This study aimed to investigate possible correlations of NAFLD with hypothalamic\u2013pituitary\u2013adrenal (HPA) axis activity and expression levels of hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptors) a (NR3C1a) and b (NR3C1b) in the liver, visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>In this single-center study, 34 severely obese patients (BMI &gt; 40 kg\/m2), scheduled to undergo bariatric surgery, were recruited and enrolled prospectively. Before the day of surgery, urinary free cortisol (UFC) and diurnal variation of serum and salivary cortisol were estimated. During surgery, biopsies of the liver, VAT, and SAT were obtained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expression of the visceral adipose tissue HSD11B1 (VAT HSD11B1) was significantly higher in the groups of patients with NAFLD (NAFLD+) or NASH (NASH+), compared with those without (NAFLD-, NASH-). The expression of NR3C1a in the liver (LNR3C1a) was significantly lower in the NAFLD+ group compared with the NAFLD- group. In the NAFLD group, the expression of HSD11B1 in the liver (LHSD11B1) exhibited a negative correlation with LNR3C1a, whereas no association was found in the NAFLD+ group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The activity of the HPA axis, and tissue and systemic cortisol levels, contribute to MetS development. There are similarities between MetS and NAFLD concerning their pathophysiological mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5114\/amsad\/209847","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:39:16Z","timestamp":1758890356000},"page":"189-197","source":"Crossref","is-referenced-by-count":0,"title":["Cortisol as a factor contributing to the development of non-alcoholic fatty liver disease in severely obese patients: a single-center prospective study"],"prefix":"10.5114","volume":"10","author":[{"given":"Petros","family":"Constantinopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Georgoulia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Theofanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Antzoulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Litsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis Dimitrios","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Liolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Leventis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Kornaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Leivaditis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesk","family":"Mulita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Skroubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref-1523652","doi-asserted-by":"crossref","unstructured":"Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults. Aliment Pharmacia Ther 2011; 34: 274-85.","DOI":"10.1111\/j.1365-2036.2011.04724.x"},{"key":"ref-1523653","doi-asserted-by":"crossref","unstructured":"Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.","DOI":"10.1002\/hep.20734"},{"key":"ref-1523654","unstructured":"Paschos P, Paletas K. Non-alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9-19."},{"key":"ref-1523655","doi-asserted-by":"crossref","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62 (1 Suppl): S47-64.","DOI":"10.1016\/j.jhep.2014.12.012"},{"key":"ref-1523656","doi-asserted-by":"crossref","unstructured":"Dyson JK, Anstee QM, McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol 2014; 5: 211-8.","DOI":"10.1136\/flgastro-2013-100403"},{"key":"ref-1523657","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.","DOI":"10.1002\/hep.25762"},{"key":"ref-1523658","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.","DOI":"10.1002\/hep.28431"},{"key":"ref-1523659","doi-asserted-by":"crossref","unstructured":"Boza C, Riquelme A, Ibanez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-53.","DOI":"10.1381\/0960892055002347"},{"key":"ref-1523660","doi-asserted-by":"crossref","unstructured":"Haentjens P, Massaad D, Reynaert H, et al. Identifying non-alcoholic fatty liver disease among asymptomatic overweight and obese individuals by clinical and biochemical characteristics. Acta Clin Belg 2009; 64:483-93.","DOI":"10.1179\/acb.2009.084"},{"key":"ref-1523662","doi-asserted-by":"crossref","unstructured":"Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45: 600-6.","DOI":"10.1016\/j.jhep.2006.06.013"},{"key":"ref-1523663","doi-asserted-by":"crossref","unstructured":"Colicchio P, Tarantino G, del Genio F, et al. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy. Ann Nutr Metab 2005; 49: 289-95.","DOI":"10.1159\/000087295"},{"key":"ref-1523664","doi-asserted-by":"crossref","unstructured":"Beymer C, Kowdley KV, Larson A, Edmonson P, Dellinger EP, Flum DR. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003; 138: 1240-4.","DOI":"10.1001\/archsurg.138.11.1240"},{"key":"ref-1523665","doi-asserted-by":"crossref","unstructured":"Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-90.","DOI":"10.1016\/j.dld.2014.09.020"},{"key":"ref-1523666","doi-asserted-by":"crossref","unstructured":"Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539\u2013553.","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"ref-1523667","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001; 285: 2486-97.","DOI":"10.1001\/jama.285.19.2486"},{"key":"ref-1523668","doi-asserted-by":"crossref","unstructured":"Alberti KG, Zimmet P, Shaw J. Metabolic syndrome \u2013 a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.","DOI":"10.1111\/j.1464-5491.2006.01858.x"},{"key":"ref-1523669","doi-asserted-by":"crossref","unstructured":"Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.","DOI":"10.1038\/414782a"},{"key":"ref-1523670","unstructured":"Obesity and overweight. Fact sheet Updated June 2016. World Health Organization (WHO). http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en\/."},{"key":"ref-1523671","doi-asserted-by":"crossref","unstructured":"Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS One 2012; 7: e29531.","DOI":"10.1371\/journal.pone.0029531"},{"key":"ref-1523672","doi-asserted-by":"crossref","unstructured":"Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11: e1001680.","DOI":"10.1371\/journal.pmed.1001680"},{"key":"ref-1523673","doi-asserted-by":"crossref","unstructured":"Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230: 258-67.","DOI":"10.1016\/j.atherosclerosis.2013.07.052"},{"key":"ref-1523674","doi-asserted-by":"crossref","unstructured":"Moon SH, Noh TS, Cho YS, et al. Association between nonalcoholic fatty liver disease and carotid artery inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Angiology 2015; 66:571-80.","DOI":"10.1177\/0003319714537872"},{"key":"ref-1523676","doi-asserted-by":"crossref","unstructured":"Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P, Targher G. Risk of cardiovascular, cardiac and arrhythmic complications in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1724-45.","DOI":"10.3748\/wjg.v20.i7.1724"},{"key":"ref-1523677","doi-asserted-by":"crossref","unstructured":"Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646-50.","DOI":"10.1016\/j.cgh.2011.12.039"},{"key":"ref-1523678","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-8.","DOI":"10.2337\/dc06-2247"},{"key":"ref-1523679","doi-asserted-by":"crossref","unstructured":"Wong VW, Wong GL, Yip GW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 2011; 60: 1721-7.","DOI":"10.1136\/gut.2011.242016"},{"key":"ref-1523680","doi-asserted-by":"crossref","unstructured":"Mirbagheri SA, Rashidi A, Abdi S, Saedi D, Abouzari M. Liver: an alarm for the heart? Liver Int 2007; 27: 891-4.","DOI":"10.1111\/j.1478-3231.2007.01531.x"},{"key":"ref-1523681","doi-asserted-by":"crossref","unstructured":"Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007; 18: 433-6.","DOI":"10.1097\/MCA.0b013e3282583c0d"},{"key":"ref-1523682","doi-asserted-by":"crossref","unstructured":"Treeprasertsuk S, Leverage S, Adams LA, Lindor KD, St SJ, Angulo P. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int 2012; 32: 945-50.","DOI":"10.1111\/j.1478-3231.2011.02753.x"},{"key":"ref-1523683","doi-asserted-by":"crossref","unstructured":"Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007; 30: 2119-21.","DOI":"10.2337\/dc07-0349"},{"key":"ref-1523684","doi-asserted-by":"crossref","unstructured":"Rabbitt EH, Lavery GG, Walker EA, Cooper MS, Stewart PM, Hewison M. Prereceptor regulation of glucocorticoid action by 11b-hydroxysteroid dehydrogenase: a novel determinant of cell proliferation. FASEB J 2002; 16: 36-44.","DOI":"10.1096\/fj.01-0582com"},{"key":"ref-1523685","doi-asserted-by":"crossref","unstructured":"Ricketts ML, Verhaeg JM, Bujalska I, Howie AJ, Rainey WE, Stewart PM. Immunohistochemical localization of type 1 11b-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metabol 1998; 83: 1325-35.","DOI":"10.1210\/jcem.83.4.4706"},{"key":"ref-1523686","doi-asserted-by":"crossref","unstructured":"Tomlinson JW, Walker EA, Bujalska IJ, et al. 11b-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr Rev 2004; 25: 831-66.","DOI":"10.1210\/er.2003-0031"},{"key":"ref-1523687","doi-asserted-by":"crossref","unstructured":"Bujalska IJ, Walker EA, Tomlinson JW, Hewison M, Stewart PM. 11b-hydroxysteroid dehydrogenase type 1 in differentiating omental human preadipocytes: from de-activation to generation of cortisol. Endocr Res 2002; 28: 449-61.","DOI":"10.1081\/ERC-120016822"},{"key":"ref-1523688","doi-asserted-by":"crossref","unstructured":"Paterson JM, Morton NM, Fievet C, et al. Metabolic syndrome without obesity: hepatic overexpression of 11b-hydroxysteroid dehydrogenase type1 in transgenic mice. PNAS 2004; 101: 7088-93.","DOI":"10.1073\/pnas.0305524101"},{"key":"ref-1523689","doi-asserted-by":"crossref","unstructured":"Candia R, Riquelme A, Baudrand R, et al. Overexpression of 11\uf062-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease. Liver Int 2012; 32: 392-9.","DOI":"10.1111\/j.1478-3231.2011.02685.x"},{"key":"ref-1523690","doi-asserted-by":"crossref","unstructured":"Stefan N, Ramsauer M, Jordan P, et al. Inhibition of 11\uf062-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014; 2: 406-16.","DOI":"10.1016\/S2213-8587(13)70170-0"},{"key":"ref-1523691","doi-asserted-by":"crossref","unstructured":"Constantinopoulos P, Michalaki M, Kottorou A, et al. Cortisol in tissue and systemic level as a contributing factor to the development of metabolic syndrome in severely obese patients. Eur J Endocrinol 2015; 172: 69-78.","DOI":"10.1530\/EJE-14-0626"},{"key":"ref-1523692","unstructured":"Waist Circumference and Waist-Hip Ratio. Report of a WHO Expert Consultation. Geneva, 8\u201311 December 2008."},{"key":"ref-1523693","doi-asserted-by":"crossref","unstructured":"Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.","DOI":"10.1053\/jhep.2003.50229"},{"key":"ref-1523694","doi-asserted-by":"crossref","unstructured":"McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59: 1265-9.","DOI":"10.1136\/gut.2010.216077"},{"key":"ref-1523695","doi-asserted-by":"crossref","unstructured":"Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004; 40: 1387-95.","DOI":"10.1002\/hep.20466"},{"key":"ref-1523696","doi-asserted-by":"crossref","unstructured":"Xia MF, Yan HM, Lin HD, et al. Elevation of liver enzymes within the normal limits and metabolic syndrome. Clin Exp Pharmacol Physiol 2011; 38: 373-9.","DOI":"10.1111\/j.1440-1681.2011.05519.x"},{"key":"ref-1523697","doi-asserted-by":"crossref","unstructured":"Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294: 2166-70.","DOI":"10.1126\/science.1066285"},{"key":"ref-1523698","doi-asserted-by":"crossref","unstructured":"Slavin BG, Ong JM, Kern PA. Hormonal regulation of hormone sensitive lipase activity and mRNA levels in isolated rat adipocytes. J Lipid Res 1994; 35: 1535-41.","DOI":"10.1016\/S0022-2275(20)41151-4"},{"key":"ref-1523699","doi-asserted-by":"crossref","unstructured":"Yang S, Xu X, Bjorntorp P. Effects of dexamethasone on primarily cultured newly differentiated rat adipocytes from different adipose tissue regions. Obes Res 1993; 1: 99-105.","DOI":"10.1002\/j.1550-8528.1993.tb00598.x"},{"key":"ref-1523700","doi-asserted-by":"crossref","unstructured":"Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non-alcoholic fatty liver disease. PLoS One 2012; 7: e29531.","DOI":"10.1371\/journal.pone.0029531"},{"key":"ref-1523701","doi-asserted-by":"crossref","unstructured":"Montague CT, O\u2019Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49: 883.","DOI":"10.2337\/diabetes.49.6.883"},{"key":"ref-1523702","doi-asserted-by":"crossref","unstructured":"Boden G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 121-4.","DOI":"10.1055\/s-2003-39781"},{"key":"ref-1523703","doi-asserted-by":"crossref","unstructured":"Mulita F, Lampropoulos C, Kehagias D, et al. Long-term nutritional deficiencies following sleeve gastrectomy: a 6-year single-centre retrospective study. Prz Menopauzalny 2021; 20: 170-6.","DOI":"10.5114\/pm.2021.110954"},{"key":"ref-1523704","doi-asserted-by":"crossref","unstructured":"Dimopoulos P, Mulita A, Antzoulas A, et al. The role of artificial intelligence and image processing in the diagnosis, treatment, and prognosis of liver cancer: a narrative-review. Gastroenterology Rev 2024; 19: 221-30.","DOI":"10.5114\/pg.2024.143147"},{"key":"ref-1523705","doi-asserted-by":"crossref","unstructured":"Verras GI, Mulita F. Butyrylcholinesterase levels correlate with surgical site infection risk and severity after colorectal surgery: a prospective single-center study. Front Surg 2024; 11: 1379410.","DOI":"10.3389\/fsurg.2024.1379410"}],"container-title":["Archives of Medical Science \u2013 Atherosclerotic Diseases"],"original-title":[],"link":[{"URL":"https:\/\/amsad.termedia.pl\/pdf-209847-129121","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/amsad.termedia.pl\/pdf-209847-129121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T12:39:33Z","timestamp":1758890373000},"score":1,"resource":{"primary":{"URL":"https:\/\/amsad.termedia.pl\/Cortisol-as-a-factor-contributing-to-the-development-of-non-alcoholic-fatty-liver,209847,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"alternative-id":["209847"],"URL":"https:\/\/doi.org\/10.5114\/amsad\/209847","relation":{},"ISSN":["2451-0629"],"issn-type":[{"value":"2451-0629","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}